Gilead in Greece
GILEAD is a research-based biopharmaceutical company that discovers, develops and delivers innovative therapeutics for people with life-threatening diseases. At Gilead, we set and achieve bold ambitions in our fight against the world’s most devastating diseases.
We are driven by our purpose of making the world a healthier place for all people. That means delivering innovative therapies that offer new hope for patients. Our ambitions have led us to a cure for hepatitis C and to transforming the treatment and prevention of HIV. Our innovation is helping people with diseases and conditions that include cancer, viral hepatitis, HIV and COVID-19.
By investing in world-class science, driving access to our medicines, addressing societal barriers to care and building a culture where our employees can make a real impact, we will continue to confront the biggest public health challenges of our day for the benefit of generations to come.
Gilead is a global company of over 17,000 employees with more than 25 currently marketed therapies. Gilead entered the Greek market in 2001, currently delivering innovative medicines to treat HIV, Hepatitis B, D and C, Haematology/Oncology, Covid-19 and Invasive Systemic Fungal Infections as well as Cystic Fibrosis.
Today, Gilead Sciences Hellas occupies 52 people focusing on medical, regulatory and commercial activities.